Tag:
Boston
Latest Headlines
Latest Headlines
Bristol-Myers Squibb marries early-stage processes to biologics manufacturing
In designing the operation, it had always intended on expanding there, adding one of the biologic products that are becoming more important to its future.
J&J stakes out Boston/Cambridge HQ for new innovation center
J&J is about to make a big entrance in the Boston/Cambridge hub. The Boston Business Journal reports today that the pharma giant has taken a lease on new digs in Kendall Square for one of its four global innovation centers--putting it right in the heart of one of the busiest biotech regions in the world.
Sanofi rebuilds early-stage R&D strategy in thriving Boston/Cambridge hub
Sanofi has had a string of regulatory successes to boast about recently. There have been approvals for Kynamro, Zaltrap, Aubagio and Lyxumia in Europe. A decision on Lemtrada is on its way. And while all sorts of questions remain over just how much money these new drugs will earn, the pharma giant's regulatory wins have eased some of the pressure to prove that it can develop new drugs and win approvals.
Bustling biotech pushes Cambridge, MA surge in VC deals, dollars
Even a casual observer of the biotech industry would know that Cambridge, MA, has seen a booming biotech sector fueled with a steady stream of venture deals. And in a year when venture deals and dollars have been considerably constricted overall, the Cambridge hub has continued to hum with VC activity.
Sanofi puts new CSO in Boston, adding more weight to U.S. R&D
The French drugmaker not only recruited a top official at the National Institutes of Health to be its chief scientific officer. It also decided to place him in the Boston area, where it set up an R&D hub last year.
Intarcia raises $210M for PhIII, once-yearly diabetes drug
Intarcia Therapeutics this morning unveiled a whopping $210 million in fresh financing to back its Phase III program for ITCA 650, which aims to be the first once-yearly, injection-free GLP-1 therapy. And the biotech says it will join the big migration to the thriving Boston hub, relocating its headquarters in California while keeping a manufacturing site in Hayward.
Wanted: New drug developers for empty R&D complex
Sanofi's decision to pull its R&D operations out of Bridgewater, NJ and relocate to Boston has left a 1.2 million-square-foot problem for state and local economic development officials to deal with.
Momenta Pharma options antibody against red meat-related inflammation
Another West Coast biotech startup has set sail for the Boston area. Sialix, a spinoff from the University of California, San Diego, has staked out office space in Cambridge, MA, and announced an option-based deal with Momenta Pharmaceuticals for its lead therapeutic antibody against a target related to ingestion of red meat and other foods.
J&J to scout early-stage deals in 4 biotech hotspots
J&J is thinking globally and acting locally, creating a plan to become a more prominent player in the field of translational medicine by setting up deal teams in four biotech hotspots around the world.
J&J fielding four global deal teams to scout early-stage drug prospects
J&J is thinking globally and acting locally, creating a plan to become a more prominent player in the field of translational medicine by setting up deal teams in four biotech hotspots around the world.
